Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

EZI Inhibitors

EZI inhibitors, short for enhancer of zeste homolog inhibitors, are a class of chemical compounds that specifically target and inhibit the function of enhancer of zeste homolog proteins, which are a central component of the polycomb repressive complex 2 (PRC2). These proteins, particularly EZH2, play a crucial role in the epigenetic regulation of gene expression through the trimethylation of lysine 27 on histone H3 (H3K27me3), a marker commonly associated with gene silencing. EZI inhibitors are designed to bind to the SET domain of EZH2, thereby preventing the methyltransferase activity of the enzyme. This inhibition leads to a decrease in H3K27me3 levels and consequently affects the epigenetic silencing of genes. By altering the histone methylation landscape, EZI inhibitors can induce changes in the expression patterns of genes that are critical for various cellular processes, including cell differentiation and proliferation.

The development of EZI inhibitors is rooted in the understanding of the molecular mechanisms by which PRC2 regulates gene expression. By binding to the active site of EZH2, these inhibitors can effectively reduce the enzymatic activity responsible for the addition of methyl groups to H3K27. The specificity of EZI inhibitors toward the SET domain is crucial, as it ensures that the off-target effects are minimized, thereby focusing the impact on the PRC2 pathway. The consequent reduction in H3K27me3 levels leads to the reactivation of previously silenced genes, which can result in pronounced changes in cellular behavior. This class of inhibitors is characterized by a range of chemical structures, each with varying degrees of affinity and specificity for the EZH2 SET domain. Researchers are continually synthesizing and evaluating novel compounds within this class to optimize their efficacy and selectivity. The biochemical pathways influenced by EZI inhibitors are complex and involve a network of interactions that extend beyond the immediate action on EZH2, affecting the broader chromatin architecture and gene expression profile of the cell.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Trichostatin A is a histone deacetylase inhibitor. EZI, being a protein that may interact with chromatin, could be indirectly inhibited by the increased acetylation of histones, leading to a conformational change in chromatin structure that disfavors EZI interactions.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

Vorinostat is another histone deacetylase inhibitor. It would enhance histone acetylation, potentially altering gene expression in a way that leads to the downregulation of EZI activity due to chromatin remodeling.

Sodium Butyrate

156-54-7sc-202341
sc-202341B
sc-202341A
sc-202341C
250 mg
5 g
25 g
500 g
$31.00
$47.00
$84.00
$222.00
19
(3)

Sodium butyrate, as a short-chain fatty acid, acts as a histone deacetylase inhibitor. It is likely to cause hyperacetylation of histones, which could disrupt the functional activity of EZI by affecting the transcription of genes that participate in its regulation.

Romidepsin

128517-07-7sc-364603
sc-364603A
1 mg
5 mg
$218.00
$634.00
1
(1)

Romidepsin is a cyclic peptide that inhibits histone deacetylase, leading to altered chromatin structure and potentially decreasing the functional activity of EZI by modifying the expression of genes critical to its function.

MS-275

209783-80-2sc-279455
sc-279455A
sc-279455B
1 mg
5 mg
25 mg
$24.00
$90.00
$212.00
24
(2)

Entinostat selectively inhibits class I histone deacetylases, leading to changes in gene expression that could result in the downregulation of EZI through epigenetic modulation.

Panobinostat

404950-80-7sc-208148
10 mg
$200.00
9
(1)

Panobinostat is a potent histone deacetylase inhibitor that could decrease EZI functional activity by broadly altering the expression patterns of genes involved in EZI-mediated pathways.

Belinostat

414864-00-9sc-269851
sc-269851A
10 mg
100 mg
$156.00
$572.00
(1)

Belinostat inhibits histone deacetylase activity, potentially reducing EZI activity by changing the expression of genes that regulate EZI's functional role in the cell.

Chidamide

743420-02-2sc-364462
sc-364462A
sc-364462B
1 mg
5 mg
25 mg
$62.00
$250.00
$1196.00
(1)

Chidamide is a histone deacetylase inhibitor that could lead to the downregulation of EZI by modifying the acetylation status of histones and thereby affecting gene expression profiles.

Valproic Acid

99-66-1sc-213144
10 g
$87.00
9
(1)

Valproic acid, commonly known as a mood stabilizer, also functions as a histone deacetylase inhibitor and could indirectly inhibit EZI by altering the transcriptional landscape that regulates EZI's activity.

Mocetinostat

726169-73-9sc-364539
sc-364539B
sc-364539A
5 mg
10 mg
50 mg
$214.00
$247.00
$1463.00
2
(1)

Mocetinostat is a selective inhibitor of class I and class IV histone deacetylases. It could indirectly lower EZI activity by changing gene expression via epigenetic remodeling.